International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 6, June 2026 ijppr.humanjournals.com ISSN: 2349-7203

Monoclonal Antibody Therapy in Autoimmune Disorders: Emerging Advances and Clinical Challenges

Ganta Neeraja[1*], Gedela Mounika[2], Hanumanthu Kodandarao[3], Mullu Naga Yesu Ravi Kumar[4], Kovvuri Surya Naga Narsireddy[5]

*1.5th Pharm.D (Doctor of Pharmacy), Lydia college of Pharmacy, Ethakota, Ravulapalem, Andhrapradesh, India.

Received: 21 April 2026 Revised: 12 May 2026 Accepted: 22 May 2026

ABSTRACT

Autoimmune diseases represent a heterogeneous group of chronic inflammatory disorders characterized by immune-mediated destruction of self-tissues resulting from loss of immunological tolerance. Conventional therapeutic approaches including corticosteroids and non-specific immunosuppressive agents have historically formed the backbone of treatment; however, their long-term use is frequently associated with systemic toxicity, limited specificity, and inadequate disease control. The advent of monoclonal antibodies (mAbs) has revolutionized autoimmune disease management by enabling selective targeting of cytokines, immune cells, receptors, and inflammatory signaling pathways involved in disease progression. Over the last two decades, monoclonal antibodies targeting tumor necrosis factor-alpha (TNF-α), CD20-positive B cells, interleukins, integrins, and interferon pathways have demonstrated remarkable therapeutic efficacy in rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, ankylosing spondylitis, and multiple sclerosis. Furthermore, advances in antibody engineering, glycoengineering, bispecific antibodies, and precision immunotherapy have significantly improved therapeutic specificity and reduced immunogenicity. Despite their clinical success, challenges including high treatment costs, infection risk, loss of therapeutic response, immunogenicity, and limited accessibility remain substantial barriers to optimal utilization. Recent developments involving artificial intelligence-assisted antibody design, biomarker-guided therapy, biosimilars, and CAR-T-cell-associated immunotherapy are expected to reshape the future of autoimmune disease treatment. This review comprehensively discusses the mechanism of action, therapeutic applications, recent advances, and clinical challenges associated with monoclonal antibodies in autoimmune diseases while emphasizing future perspectives for personalized medicine and targeted immunotherapy.

Keywords: Monoclonal antibodies, biologics, immunotherapy, TNF inhibitors, rituximab, precision medicine.

INTRODUCTION

Autoimmune diseases are chronic disorders resulting from dysregulated immune responses against self-antigens, leading to progressive tissue damage and organ dysfunction.[1] More than 80 autoimmune disorders have been identified, collectively affecting millions of individuals worldwide and contributing significantly to global morbidity and healthcare expenditure.[2] Common autoimmune diseases include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, inflammatory bowel disease (IBD), multiple sclerosis (MS), and ankylosing spondylitis.[3]

The pathogenesis of autoimmune diseases is multifactorial and involves genetic predisposition, environmental triggers, hormonal influences, microbial factors, and immune dysregulation.[4] Central to disease progression is the loss of immunological tolerance, resulting in activation of autoreactive T cells, B cells, and excessive production of pro-inflammatory cytokines such as TNF-α, IL-6, IL-17, and interferons.[5]

Historically, autoimmune diseases were managed using corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and conventional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate and azathioprine.[6] Although these therapies reduced inflammation and delayed disease progression, they lacked specificity and were associated with severe adverse effects such as hepatotoxicity, nephrotoxicity, bone marrow suppression, metabolic complications, and generalized immunosuppression.[7]

The development of monoclonal antibodies marked a major milestone in immunotherapy and transformed the management of autoimmune disorders.[8] Monoclonal antibodies are highly specific immunoglobulins engineered to selectively target pathological

immune pathways involved in disease progression.[9] Unlike traditional immunosuppressants, mAbs provide targeted therapeutic action with improved efficacy and comparatively reduced systemic toxicity.[10]

The first successful anti-TNF monoclonal antibody therapies dramatically improved clinical outcomes in rheumatoid arthritis and inflammatory bowel disease, paving the way for a new era of biologic medicine.[11] Since then, numerous monoclonal antibodies targeting cytokines, B cells, T-cell co-stimulation pathways, and immune receptors have received regulatory approval for various autoimmune disorders.[12]

Recent advances in biotechnology, antibody engineering, glycoengineering, nanobody technology, bispecific antibodies, and artificial intelligence-assisted drug discovery are further enhancing the therapeutic potential of monoclonal antibodies.[13] However, despite remarkable clinical success, several challenges including high cost, immunogenicity, infection risk, treatment resistance, and accessibility limitations continue to affect widespread utilization.[14]

This review aims to provide a comprehensive overview of the role of monoclonal antibodies in autoimmune diseases, including their mechanisms of action, therapeutic applications, recent advances, clinical challenges, and future perspectives relevant to modern Pharm D education and clinical practice.

Overview of Monoclonal Antibodies

Monoclonal antibodies are laboratory-produced immunoglobulins generated from a single clone of B lymphocytes and designed to bind specifically to a particular antigen.[15] They are produced using hybridoma technology or recombinant DNA techniques and have become essential therapeutic tools in oncology, immunology, and autoimmune medicine.[16]

Classification of Monoclonal Antibodies

Monoclonal antibodies are classified according to their structural composition and degree of humanization:

Type	Suffix	Source	Immunogenicity
Murine	-omab	Entirely mouse-derived	High
Chimeric	-ximab	Mouse-human hybrid	Moderate
Humanized	-zumab	Mostly human with murine antigen-binding regions	Low
Fully Human	-umab	Completely human-derived	Very low

Humanized and fully human monoclonal antibodies are preferred in clinical practice because they exhibit reduced immunogenicity and improved tolerability.[17]

Mechanism of Action of Monoclonal Antibodies

Monoclonal antibodies exert therapeutic effects through multiple immunological mechanisms depending on their target antigen.[18]

1. Cytokine Neutralization

Certain monoclonal antibodies bind directly to inflammatory cytokines such as TNF-α or IL-6 and prevent receptor-mediated signaling pathways involved in inflammation and tissue destruction.[19]

2. Immune Cell Depletion

Agents such as rituximab selectively deplete CD20-positive B cells through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.[20]

3. Receptor Blockade

Monoclonal antibodies may block receptor activation, thereby inhibiting downstream inflammatory signaling pathways.[21]

4. Inhibition of Leukocyte Migration

Integrin-targeting antibodies prevent migration of inflammatory immune cells into tissues affected by autoimmune inflammation.[22]

5. Modulation of Immune Signaling

Certain antibodies alter T-cell activation and cytokine release, restoring immune balance and reducing chronic inflammation.[23]

Pathophysiology of Autoimmune Diseases and Therapeutic Targets

Autoimmune diseases arise when the immune system loses tolerance toward self-antigens and mistakenly attacks normal tissues.[24] The pathological process involves activation of autoreactive T lymphocytes, B-cell proliferation, cytokine overproduction, and chronic inflammatory responses.[25]

Genetic susceptibility plays an important role in autoimmune disorders. Human leukocyte antigen (HLA) genes are strongly associated with diseases such as rheumatoid arthritis and type 1 diabetes mellitus.[26] Environmental triggers including infections, smoking, ultraviolet radiation, stress, and dietary factors further contribute to disease onset and progression.[27]

Key inflammatory mediators involved in autoimmune disease pathogenesis include:

Therapeutic Target Role in Autoimmune Disease

TNF-α Promotes chronic inflammation and tissue destruction

IL-6 Stimulates B-cell differentiation and systemic inflammation

IL-17 Induces neutrophil recruitment and autoimmune tissue injury

CD20 Supports B-cell survival and autoantibody production

Integrins Facilitate immune cell migration into inflamed tissues

IFN-α Contributes to lupus-associated immune activation

Monoclonal antibodies selectively target these pathways and interrupt disease progression while minimizing generalized immunosuppression.[28]

Major Monoclonal Antibodies Used in Autoimmune Diseases

Anti-TNF Monoclonal Antibodies

Tumor necrosis factor-alpha (TNF-α) is a central pro-inflammatory cytokine implicated in autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis.[29]

Common Anti-TNF Agents

Infliximab

Adalimumab

Golimumab

Certolizumab pegol

These agents significantly reduce inflammation, improve clinical symptoms, prevent joint destruction, and enhance patient quality of life.[30]

Infliximab

Infliximab is a chimeric monoclonal antibody that binds TNF-α and inhibits inflammatory signaling.[31] It has demonstrated remarkable efficacy in rheumatoid arthritis and inflammatory bowel disease.

Adalimumab

Adalimumab is a fully human monoclonal antibody widely used in autoimmune disorders because of its strong efficacy and lower immunogenicity.[32]

Anti-TNF therapy revolutionized autoimmune disease management and remains a cornerstone of biologic therapy worldwide.[33]

Anti-CD20 Monoclonal Antibodies

B cells play a critical role in autoimmune diseases through autoantibody production, antigen presentation, and cytokine secretion.[34]

Rituximab

Rituximab selectively targets CD20-positive B lymphocytes leading to B-cell depletion.[35] It is approved for rheumatoid arthritis, vasculitis, pemphigus vulgaris, and several neurological autoimmune disorders.

Clinical studies have demonstrated significant reduction in disease activity and improved remission rates with rituximab therapy.[36]

Ocrelizumab

Ocrelizumab is a humanized anti-CD20 monoclonal antibody primarily used in multiple sclerosis.[37] It reduces relapse rates and slows disease progression by targeting pathogenic B cells.

Anti-Interleukin Monoclonal Antibodies

Interleukins are key mediators of inflammatory responses and have emerged as important therapeutic targets in autoimmune diseases.[38]

Tocilizumab

Tocilizumab inhibits IL-6 receptor signaling and is highly effective in rheumatoid arthritis and cytokine-mediated inflammatory conditions.[39]

Secukinumab

Secukinumab targets IL-17A and is widely used in psoriasis and ankylosing spondylitis.[40]

Ustekinumab

Ustekinumab inhibits IL-12 and IL-23 pathways involved in psoriasis and inflammatory bowel disease.[41]

Integrin-Targeting Monoclonal Antibodies

Natalizumab

Natalizumab inhibits leukocyte migration across the blood-brain barrier and is used in multiple sclerosis and Crohn's disease.[42]

Vedolizumab

Vedolizumab selectively targets gut-specific integrins and is used in ulcerative colitis and Crohn's disease.[43]

Role of Monoclonal Antibodies in Specific Autoimmune Diseases

Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune inflammatory disorder characterized by synovial inflammation, cartilage destruction, and progressive joint deformity.[44]

Monoclonal antibodies targeting TNF-α, IL-6, and CD20 have substantially improved disease management.[45] Combination therapy involving biologics and methotrexate demonstrates superior efficacy compared with conventional DMARD therapy alone.[46]

Long-term biologic therapy has shown reduced radiographic progression and improved functional outcomes in RA patients.[47]

Systemic Lupus Erythematosus

Systemic lupus erythematosus is a multisystem autoimmune disease associated with autoantibody production and immune-complex-mediated tissue injury.[48]

Belimumab

Belimumab inhibits B-cell activating factor (BAFF) and reduces survival of autoreactive B cells.[49]

Anifrolumab

Anifrolumab blocks type I interferon receptor signaling, a key pathway implicated in lupus pathogenesis.[50]

Recent biologic therapies have reduced corticosteroid dependence and improved long-term organ protection in SLE patients.[51]

Psoriasis

Psoriasis is an immune-mediated inflammatory skin disorder involving TNF-α, IL-17, and IL-23 pathways.[52]

Biologic therapies such as secukinumab and ustekinumab provide superior skin clearance and prolonged remission compared with conventional systemic therapies.[53]

Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune demyelinating disorder of the central nervous system.[54]

Monoclonal antibodies including natalizumab and ocrelizumab reduce relapse rates, decrease inflammatory lesions, and slow neurological deterioration.[55]

Inflammatory Bowel Disease

Inflammatory bowel disease comprises Crohn's disease and ulcerative colitis characterized by chronic gastrointestinal inflammation.[56]


Anti-TNF agents and integrin-targeting antibodies have significantly improved remission rates and mucosal healing in IBD patients.[57]

Current Advances in Monoclonal Antibody Therapy

Humanization and Glycoengineering

Advancements in antibody engineering have significantly reduced immunogenicity and improved pharmacokinetic profiles.[58]

Glycoengineering techniques modify Fc glycosylation patterns to enhance antibody-dependent cellular cytotoxicity and therapeutic efficacy.[59]



Bispecific Monoclonal Antibodies

Bispecific antibodies simultaneously target two different antigens or immune pathways.[60] These next-generation biologics may improve therapeutic precision and overcome resistance associated with single-target therapy.

Emerging bispecific antibodies are currently being investigated for refractory autoimmune diseases and severe inflammatory conditions.[61]

CAR-T Cell-Associated Strategies

Chimeric antigen receptor T-cell (CAR-T) therapy originally developed for hematological malignancies is now being explored for severe autoimmune diseases.[62]

CAR-T-associated immunotherapy enables targeted elimination of autoreactive immune cells and may provide long-term remission in refractory autoimmune disorders.[63]

Artificial Intelligence in Antibody Design

Artificial intelligence and computational biology are increasingly being used in monoclonal antibody discovery and optimization.[64]

AI-assisted platforms help predict antigen-binding affinity, antibody stability, immunogenicity, and molecular interactions, thereby accelerating biologic drug development.[65]

Biosimilars and Improved Accessibility

Biosimilars are biologic products highly similar to approved reference monoclonal antibodies.[66] They offer reduced treatment cost and improved accessibility without compromising efficacy or safety.

The introduction of biosimilars has expanded biologic therapy availability in developing countries and resource-limited healthcare systems.[67]

Clinical Challenges and Limitations

Despite remarkable therapeutic success, monoclonal antibodies are associated with several important clinical challenges.

Immunogenicity

Patients receiving monoclonal antibodies may develop anti-drug antibodies that reduce therapeutic efficacy and increase hypersensitivity reactions.[68]

Although humanized and fully human antibodies exhibit lower immunogenicity, the problem has not been completely eliminated.[69]

Increased Risk of Infections

Because biologic agents suppress immune pathways, they increase susceptibility to opportunistic infections including tuberculosis, fungal infections, and viral reactivation.[70]

Screening for latent tuberculosis and hepatitis infection is recommended before initiating biologic therapy.[71]

High Cost of Therapy

Monoclonal antibodies are expensive because of complex manufacturing processes, cold-chain storage requirements, and extensive clinical development.[72]

Limited affordability remains a major concern in low- and middle-income countries.[73]

Loss of Therapeutic Response

Some patients experience primary or secondary non-response following prolonged biologic therapy.[74]

Therapeutic drug monitoring and switching between biologics are commonly used strategies to overcome treatment failure.[75]

Safety Concerns

Potential adverse effects associated with monoclonal antibodies include:

Infusion reactions

Cytopenias

Hepatotoxicity

Malignancy risk

Demyelinating disorders

Autoimmune complications

Careful patient selection and long-term monitoring are therefore essential.[76]

Future Perspectives

The future of monoclonal antibody therapy is moving toward precision medicine and individualized immunotherapy.[77]


Biomarker-guided therapy may help clinicians identify patients most likely to respond to specific biologics while minimizing adverse effects.[78]

Nanobody technology, Fc-engineered antibodies, and gene-based immune modulation are expected to further enhance treatment efficacy.[79]

Artificial intelligence-assisted drug discovery may accelerate development of highly selective monoclonal antibodies with reduced immunogenicity and improved safety profiles.[80]

Emerging concepts such as antigen-specific immune tolerance and inverse vaccines may eventually allow selective suppression of pathogenic immune responses without generalized immunosuppression.[81]

Additionally, increasing availability of biosimilars is expected to reduce treatment costs and improve accessibility globally.[82]



Conclusion

Monoclonal antibodies have fundamentally transformed the management of autoimmune diseases by enabling highly targeted immunotherapy directed against specific inflammatory pathways and immune mediators. Their remarkable efficacy in rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and multiple sclerosis has significantly improved patient outcomes and quality of life.

Recent advances including antibody humanization, glycoengineering, bispecific antibodies, CAR-T-associated immunotherapy, biosimilars, and artificial intelligence-assisted antibody design are expanding the therapeutic horizon of autoimmune medicine.

Despite substantial progress, challenges including immunogenicity, infection risk, treatment resistance, safety concerns, and high cost continue to affect long-term clinical success.

Future research focusing on personalized medicine, biomarker-guided therapy, and next-generation biologics is expected to further optimize therapeutic efficacy, safety, and accessibility. With continuous advancements in biotechnology and immunology, monoclonal antibodies are likely to remain central to the future management of autoimmune diseases.

Funding Statement

The authors received no financial support for the preparation of this manuscript.

Acknowledgement

The authors sincerely acknowledge academic mentors, faculty members, and researchers whose scientific contributions in the field of immunology and biologics inspired the preparation of this review article.

REFERENCES

1. Rose NR, Mackay IR. The autoimmune diseases. 6th ed. London: Academic Press; 2019.
2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-50.
3. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's textbook of rheumatology. 11th ed. Philadelphia: Elsevier; 2021.
4. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119-25.
5. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37.
6. Katzung BG. Basic and clinical pharmacology. 15th ed. New York: McGraw-Hill; 2021.
7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman and Gilman's the pharmacological basis of therapeutics. 14th ed. New York: McGraw-Hill; 2023.
8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7.
9. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
10. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301-16.
11. Feldmann M, Maini RN. Anti-TNF therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-96.
12. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-108.
13. Kaplon H, Reichert JM. Antibodies to watch in 2024. MAbs. 2024;16(1):2334997.
14. Harris CT, Cohen S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs. 2024;38:205-26.
15. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 11th ed. Philadelphia: Elsevier; 2024.
16. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009;27(4):331-7.
17. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. MAbs. 2010;2(3):256-65.
18. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361-70.
19. Croft M, Salek-Ardakani S, Ware CF. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat Rev Drug Discov. 2024;23:939-61.
20. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
21. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220-33.

22. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4(4):571-80.
23. Murphy K, Weaver C. Janeway's immunobiology. 10th ed. New York: Garland Science; 2022.
24. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-24.
25. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006;18(5):468-75.
26. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. Arthritis Rheum. 1987;30(11):1205-13.
27. Miller FW, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun. 2012;39(4):253-8.
28. Robinson WH, Fiorentino D, Chung L, Moreland LW, Deodhar M, Harler MB, et al. Cutting-edge approaches to B-cell depletion in autoimmune diseases. Front Immunol. 2024;15:1454747.
29. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action. Pharmacol Ther. 2008;117(2):244-79.
30. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab in rheumatoid arthritis. Lancet. 1999;354(9194):1932-9.
31. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease. Lancet. 2002;359(9317):1541-9.
32. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic outcomes in rheumatoid arthritis patients treated with adalimumab. Arthritis Rheum. 2004;50(5):1400-11.
33. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38.
34. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther. 2003;5(Suppl 4):S1-6.
35. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab. Arthritis Rheum. 2006;54(2):613-20.
36. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. Rituximab in rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1390-400.
37. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in multiple sclerosis. N Engl J Med. 2017;376:221-34.
38. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation. Nat Med. 2013;19(7):822-4.
39. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Tocilizumab in rheumatoid arthritis. N Engl J Med. 2010;362(15):1420-30.
40. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis. N Engl J Med. 2014;371:326-38.
41. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab in Crohn's disease. N Engl J Med. 2016;375:1946-60.
42. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. Natalizumab in multiple sclerosis. N Engl J Med. 2006;354:899-910.
43. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
44. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis. JAMA. 2018;320(13):1360-72.
45. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-48.
46. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. American College of Rheumatology guideline for rheumatoid arthritis treatment. Arthritis Care Res. 2016;68(1):1-25.
47. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease remission and radiographic progression in rheumatoid arthritis. Arthritis Rheum. 2008;58(2):S126-35.
48. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878-88.
49. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Belimumab in systemic lupus erythematosus. Lancet. 2011;377(9767):721-31.
50. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211-21.
51. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. EULAR recommendations for SLE management. Ann Rheum Dis. 2019;78(6):736-45.
52. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
53. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301-15.
54. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169-80.
55. Hauser SL, Cree BAC. Treatment of multiple sclerosis. Ann Neurol. 2020;87(2):183-200.
56. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-70.
57. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-55.

58. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and glycoengineering. MAbs. 2011;3(5):415-6.
59. Beyzae A, Larroque C, Le Quintrec M. Role of antibody glycosylation in autoimmune disease. Nat Rev Nephrol. 2024;20:672-89.
60. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review. Nat Rev Drug Discov. 2019;18:585-608.
61. Wu X, Demarest SJ. Building blocks for bispecific and trispecific antibodies. Methods. 2019;154:3-9.
62. Chung JB, Brudno JN, Borie D, Kochenderfer JN, et al. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830-45.
63. Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory autoimmune disease. N Engl J Med. 2021;385:567-9.
64. Kenlay H, Dreyer FA, Cutting D, Nissley D, Deane CM. ABodyBuilder3: scalable antibody structure predictions. arXiv. 2024.
65. Marks C, Deane CM. How artificial intelligence is transforming antibody discovery. Trends Pharmacol Sci. 2020;41(9):687-700.
66. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111-7.
67. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for biosimilars. Ann Rheum Dis. 2018;77(2):165-74.
68. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics. BioDrugs. 2010;24(1):1-17.
69. Harding FA, Stickler MM, Razo J, DuBridge RB. Immunogenicity of fully human antibodies. MAbs. 2010;2(3):256-65.
70. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in anti-TNF therapy. Ann Rheum Dis. 2010;69(3):522-8.
71. Winthrop KL. The emerging safety profile of biologic therapies. Nat Rev Rheumatol. 2017;13(4):234-43.
72. Blackstone EA, Fuhr JP Jr. Innovation and competition in biologics. Nat Rev Drug Discov. 2013;12(10):817-8.
73. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in biologic therapy access. Ann Rheum Dis. 2014;73(1):198-206.
74. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments. Aliment Pharmacol Ther. 2011;33(9):987-95.
75. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Therapeutic drug monitoring in biologic therapy. Gastroenterology. 2017;153(3):835-46.
76. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology. Nat Rev Drug Discov. 2007;6(1):75-92.
77. Smolen JS, Aletaha D. Precision medicine in rheumatology. Lancet. 2015;386(9997):1011-2.
78. Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Biomarker-guided therapy in rheumatoid arthritis. Lancet. 2021;397(10271):386-97.
79. Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based therapeutics. Front Immunol. 2017;8:1603.
80. Pereira P, Minoux H, Walczak AM, Mora T. Energy-based generative models for monoclonal antibodies. arXiv. 2024.
81. Serra P, Santamaria P. Antigen-specific therapeutic approaches in autoimmunity. Nat Biotechnol. 2019;37(3):238-51.
82. Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, et al. Biosimilars in autoimmune diseases. Ann Rheum Dis. 2018;77(2):165-74.

How to cite this article:
Ganta Neeraja et al. Ijppr.Human, 2026; Vol. 32 (6):63-73.

Conflict of Interest Statement: All authors have nothing else to disclose.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.